99¦~04¤ë¸¹ ¹D ªk ªk °T (216)

DEEP & FAR

 

 

¯B¤ô¦L¬y¦æ¯f¾Ç¦]ªGÃö«Y¤§±Òµo

 

 

±i¬f²W «ß®v

¡D¬Fªv¤j¾Çªk«ß¾Ç¨t¾Ç¤h

¡D¬Fªv¤j¾Çªk«ß¾Ç¬ã¨s©ÒºÓ¤h

¡D«ß®v°ª¦Ò¤Î®æ

 

²Ä¤G¸`¡@¬ü°êªk¤W©Ó»{¬ì¾ÇÃÒ¾Ú¤§°ò¥»­ì«h

²Ä¤G¶µ¡@Áp¨¹ÃÒ¾Úªk¤§¬ÛÃö³W½d

¦bFrye­ì«h¤§«á¡AÁp¨¹ÃÒ¾Úªk¨î­q¨Ã¥B¬I¦æ¡A¦ü¥G¦³©ñ¼e¡u¹ï©ó±M®a¬ì¾ÇÃÒ¾Ú¤§©Ó»{¼Ð·Ç¡v¤§¶É¦V¡C¨Ì¾ÚÁp¨¹ÃÒ¾Úªk402±ø¤§³W©w¡A©Ò¦³¨ã¦³ÃöÁp©ÊªºÃÒ¾Ú³£¨ã¦³¥i©Ó»{©Ê¡C¦Ü©ó©Ò¿×¨ã¦³ÃöÁp©ÊªºÃÒ¾Ú¡A§Y¸ÓºØÃҾڨ㦳¬YºØ¶É¦V¡]tendency¡^¡A¯à¨Ï¦b¶D³^»{©w¤W¨ã¦³­«­n©Êªº¨Æ¹ê¦s¦b¡A§ó¥[¦a¥i«H¡]more probable¡^©Î§ó¥[¦a¤£¥i«H¡]less probable¡^¡C¥t¥~¡A¹ï©ó±M®aÃÒ¨¥ªº¥D­n³W½d«h¬O¦bÁp¨¹ÃÒ¾Úªk702±ø¥H¤Î703±ø¡C702±ø³W©w¡A¡u¦pªG¬ì¾Ç¡B§Þ³N©Î±M·~ª¾ÃѱNÀ°§U³­¼f­û²z¸ÑÃÒ¾Ú¡A©ÎªÌ¦³§U©ó»{©wª§Ä³¨Æ¹ê¡A¤@¦ì¥Ñ©óª¾ÃÑ¡B§Þ¯à¡B¸gÅç¡B°V½m¡B©Î±Ð¨|¦Ó³Q»{¬°¨ã³Æ±M®a¸ê®æ¤§ÃÒ¤H¡A¦b¤U¦C±¡ªp¤U¡A¥i¥H¥H·N¨£©Î¨ä¥Lªº§Î¦¡§@ÃÒ¡G1. ¦¹ÃÒ¨¥¬O¥H¥R¤Àªº¨Æ¹ê©Î¼Æ¾Ú¸ê®Æ¬°°ò¦¡F2. ¸ÓÃÒ¨¥¬O¥i¾aªº­ì«h¤Î¤èªk¤§²£ª«¡F3. ¸ÓÃÒ¤H¥i¾a¡B½T¹ê¦a±N³o¨Ç­ì«h¤Î¤èªk¾A¥Î¨ì¸Ó®×ªº¨Æ¹ê¤W¡v¡C·íÁp¨¹ÃÒ¾Úªk¬I¦æ«á¡A¤@¨ÇÁp¨¹¨µ°jªk°|¡]Federal circuit court¡^©ñ±ó¤FFrye­ì«h¡FµM¦Ó¡A¬Y¨Çªk°|¤´µMÄ~Äò¾A¥Î¡A©Î¬O±NFrye­ì«h·t¤¤¸ÑŪ¬°Áp¨¹ÃÒ¾Úªkªº¤@³¡¤À¡C±µ¤U¨Ó­n°Q½×ªºDaubert¤@®×´N¬OÄÝ©ó«áªÌ¡C

 

²Ä¤T¶µ¡@Daubert v. Merrell Dow Pharmaceuticals, Inc¤@®×

¬Û¸û©ó¨ä¥L§P¨M¡A¦¹®×¦b¬O§_©Ó»{±M®a¡B¬ì¾ÇÃÒ¾Úªº½ÒÃD¤W¡A§êºt¤FÁ|¨¬»´­«ªº¦a¦ì¡C©óDaubert®×¤¤¡A³Ì°ªªk°|ªk©x¥þÅé¤@­P¦P·N¡AFrye­ì«h¤w³QÁp¨¹ÃÒ¾Úªk702±ø©Ò¨ú¥N¡A¨Ã¥B´£¥X¡uÂù­«­n¨D¡v¡]two-pronged¡^¤§ÀËÅç¡C¨ä»{¬°Áp¨¹ÃÒ¾Úªk©Ò­n¨Dªº¤£¶È¶È¬OÃöÁp©Ê¦Ó¤w¡AÁp¨¹ÃÒ¾Úªk702±ø  °£¤FÃöÁp©Ê¡A¤]­n¨D¥i¾a©Ê¡B½T¹ê©Ê¡]Reliability¡^¡F¦]¦¹ÃÒ¨¥©ÎÃҾڨ㦳ÃöÁp©Ê¡A¦ý¤£¨ã¦³¥i¾a©Ê¡B½T¹ê©ÊªÌ¡A¤´Äݩ󤣳Q©Ó»{ªºÃÒ¾Ú¡CÃö©ó¥i¾a©Ê¡B½T¹ê©Ê¡ADaubert®×¤§³Ì°ªªk°|»{¬°¡A©Ò¿×¥i¾a¡B½T¹êªº·N¨£¤Î±À½×¡A¬O¸g¥Ñ¬ì¾Çªº¤èªk¤Îµ{§Ç¦Ó¹F¦¨¡F¦b¯A¤Î¬ì¾ÇÃÒ¾Ú¤§®×¥ó¤¤¡AÃÒ¾Ú¤W¤§¥i¾a¡B½T¹ê©Ê¥²¶·¥H¬ì¾Ç¤W¤§¦³®Ä©Ê¡]scientific validity¡^§@¬°°ò¦¡C¦Ü©ó¦p¦ó§PÂ_¡B¿Å¶q¬YÃÒ¨¥¡BÃÒ¾Ú¬O§_¨ã³Æ¥i¾a¡B½T¹ê©Ê¡A©Î¬O¬ì¾Ç¤W¤§¦³®Ä©Ê¡ADaubert®×ªk°|´£¥X¤F¥|¶µ¤£¨ã±Æ¥L©Êªº¿Å¶q°ò·Ç¡G

1.      ¸Ó±M®a¤§²z½×¡B§Þ³N©Î¤èªk¬O§_¤w¸g³QÀËÅç¡B´ú¸Õ¡A©ÎªÌ¯à§_³QÀËÅç¡B´ú¸Õ¡F

2.      ¸Ó¶µ¬ã¨s¤èªk¥i¯àªº¿ù»~¾÷²v¡]potential rate of error¡^¡F

3.      ¸Ó¶µ²z½×©ÎªÌ§Þ³N¬O§_¤w¸g¹L¦P¾«¼f®Ö¡]peer review¡^¡A©ÎªÌ¸Ó¶µ¬ã¨sµ²ªG¬O§_¤w¸g¹L¤½¶}µoªí¡]published¡^¡F

4.      ¸Ó±M®a¤§¤èªk¡B§Þ³N¦b¬ÛÃöªº¬ì¾Ç»â°ì¤¤¬O§_Àò±o´¶¹M¦a±µ¨ü¡]general acceptance¡^¡C

¥Ñ¦¹¥i¨£¡AÁöµMDaubert®×³Ì°ªªk°|ªí­±¤W±Æ¥¸Frye­ì«h¡A¦ýFrye­ì«h¤§®Ö¤ß­n¥ó¡u´¶¹M¦a±µ¨ü¡v¡A¤´µM¥H¨ä¥Lªº§Î¦¡¥Í¦s¤U¨Ó¡CDaubert¤@®×±a¨Ó¨â­Ó­«­nªº¼vÅT¡A¨ä¤@¬°¡A­«·s©w¦ìªì¼fªk°|¦uªù­û¡]Gate-keeping¡^ªº¨¤¦â¡CÁöµMªì¼fªk°|­ì¥»´N¦³Åv­­±Æ°£¤£¾A·íªº±M®aÃÒ¾Ú¡A¦ýDaubert®×§ó±j½Õªì¼fªk°|¦æ¨Ï¦¹¶µÅv­­¤§¸q°È¡C¥t¤@¶µ­«­nªº¼vÅT¬O¡A¦¹§P¨M«D±`­«µøªk«ß»P¬ì¾Ç¤§¿Ä¦X¡B¥æ¶°¡C¸Ó§P¨M¤§¦h¼Æ·N¨£«ü¥X¡Aªk°|¥²¶·´x´¤¤w¸g«Ø¥ßªº¡B¥H¤Î­è¯B²{ªº¬ì¾ÇijÃD¡F¨Ã¥B±j½Õªk°|¦b´x´¤³o¨ÇijÃD®É¡A¥²¶·¥Hªk«ß¤H¡A¦Ó«D¬ì¾Ç®a¡AªºÆ[ÂI¬°¤§¡C